BRISTOL-MYERS SQUIBB COMPANY

Official Publications Bristol-Myers Squibb Company Swiss Exchange

Equities

BMY

US1101221083

Delayed Swiss Exchange Other stock markets 11:35:20 2019-06-28 EDT			5-day change	1st Jan Change
44.39 ^CHF	-0.25%		-18.16%	-18.16%

07-02	Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	CI
07-01	Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	MT

Official Publications

SEC Filing 10Q-1	23-04-26	CO
Slide show Q1	23-04-26	CO
1st quarter results	23-04-26	CO
Annual Report	23-04-26	CO
SEC Filing 8K	23-04-26	CO
SEC Filing 8K	23-04-25	CO
Proxy Statments	23-03-22	CO
SEC Filing 10K	23-02-13	CO
Slide show results	23-02-01	CO
Annual results	23-02-01	CO
SEC Filing 8K	23-02-01	CO
SEC Filing 8K	23-01-30	CO
SEC Filing 8K	23-01-08	CO
Slide show Q3	22-10-25	CO
3rd quarter results	22-10-25	CO
SEC Filing 10Q-2	22-10-25	CO
SEC Filing 8K	22-10-25	CO
SEC Filing 8K	22-07-26	CO
SEC Filing 10Q-2	22-07-26	CO
1st-half-year results	22-07-26	CO
Slide show half-year results	22-07-26	CO
SEC Filing 4K	22-06-15	CO
SEC Filing 8K	22-06-14	CO
Dividends	22-06-14	CO
Slide show Q1	22-04-28	CO

1 2 3

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer